- Conditions
- Colorectal Cancer, Gastric Cancer, Locally Advanced or Metastatic Solid Tumors, Pancreatic Cancer
- Interventions
- MRG007
- Drug
- Lead sponsor
- ArriVent BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Condition Directory
Gastric Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Gastric Cancer. Browse Gastric Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 22, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
275
Shown on this page
12
Local recruiting
63
Local phase groups
6
How Gastric Cancer studies are organized in the registry
Gastric cancer studies are often registered together with gastroesophageal junction (GEJ) tumors, and many list both. HER2 status appears in this portfolio as well, marking a biomarker-defined subset. Including “gastroesophageal” in a query surfaces records that a plain “gastric” search can miss.
- 23% of the 275 locally indexed Gastric Cancer records are currently marked recruiting.
- The most common phase group in the local index is Phase 1 (127 records).
- The most frequent sponsor is Memorial Sloan Kettering Cancer Center (15 records).
- The most listed study location is New York, New York (75 records).
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 1–12 of 275 matching trials for Gastric Cancer.
Indexed local directory records.
Phase distribution
Phase 1 127
Phase 2 126
Phase 3 19
Not applicable 13
Phase 4 3
Early Phase 1 1
Top locations
Top sponsors
Top therapies
Indexed official records
Open in full search- Conditions
- Biliary Tract Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- AZD4360
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Providence, Rhode Island • Houston, Texas
- Conditions
- Bladder Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Mesothelioma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Pheochromocytoma/Paraganglioma (PPGL), Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
- Interventions
- [18F]FAPI-74, [18F]FDG
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Gastric Cancer
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Advanced Solid Tumor, Bladder Cancer, Breast Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Non-small Cell Lung Cancer (NSCLC), Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Cancer
- Interventions
- HER3-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 13
- States / cities
- Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 10 more
- Conditions
- Gastric Cancer
- Interventions
- Observational study (no intervention)
- Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Advanced Cancer, Esophageal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Carcinoma, Metastatic Cancer, Solid Tumor
- Interventions
- 5Fluorouracil, Capecitabine, Givastomig, Leucovorin, Nivolumab, Oxaliplatin
- Drug
- Lead sponsor
- I-Mab Biopharma US Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Goodyear, Arizona • Duarte, California • Boston, Massachusetts
- Conditions
- Gastric Cancer
- Interventions
- 5-Fluorouracil, AZD0901, Capecitabine, FOLFOX, Rilvegostomig, Volrustomig, XELOX
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Baton Rouge, Louisiana • Grand Rapids, Michigan + 5 more
- Conditions
- Gastric Cancer
- Interventions
- Capecitabine, Cisplatin, Durvalumab, Fluorouracil (5-FU), Oxaliplatin, Pembrolizumab, Rilvegostomig, Trastuzumab, Trastuzumab deruxtecan, Volrustomig
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Santa Monica, California • Westwood, Kansas • Baltimore, Maryland + 6 more
- Conditions
- Advanced Solid Tumor, Bladder Cancer, Breast Cancer, Endometrial Cancer, Gastric Cancer, GastroEsophageal Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Ovarian Cancer, Prostate Cancer, Small Cell Lung Cancer, TNBC - Triple-Negative Breast Cancer
- Interventions
- BG-68501, BGB-43395, Fulvestrant
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
- Conditions
- Cervical Cancer, Clear Cell RCC, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, HCC, HNSCC, Locally Advanced or Metastatic Solid Tumors, Melanoma, NSCLC, TNBC, Urothelial Carcinoma
- Interventions
- Atezolizumab, Enzelkitug, Pembrolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 11
- States / cities
- San Francisco, California • Aurora, Colorado • Sarasota, Florida + 8 more
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Interventions
- IKS014
- Drug
- Lead sponsor
- Iksuda Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Newport Beach, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
About this Gastric Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Gastric Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Gastric Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Gastric Cancer.